Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Stryker Co. (NYSE:SYK - Get Rating) has received a consensus recommendation of "Moderate Buy" from the nineteen analysts that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $256.00.

Several research firms have recently weighed in on SYK. TheStreet lowered Stryker from a "b" rating to a "c+" rating in a research report on Monday, May 2nd. Cowen decreased their target price on Stryker from $305.00 to $233.00 and set an "outperform" rating for the company in a research report on Friday, July 22nd. Deutsche Bank Aktiengesellschaft downgraded Stryker from a "buy" rating to a "hold" rating and cut their price target for the company from $285.00 to $205.00 in a research note on Thursday, July 21st. Citigroup cut their target price on Stryker from $310.00 to $280.00 in a research note on Tuesday, May 17th. Finally, Stifel Nicolaus dropped their price objective on Stryker from $285.00 to $245.00 in a research note on Monday, July 18th.Stryker Stock Performance

Shares of NYSE SYK opened at $215.79 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.15 and a current ratio of 2.00. The stock has a 50 day moving average price of $207.39 and a 200 day moving average price of $237.09. The stock has a market capitalization of $81.60 billion, a PE ratio of 39.74, a price-to-earnings-growth ratio of 2.60 and a beta of 1.03. Stryker has a 52 week low of $188.84 and a 52 week high of $281.16.

Stryker (NYSE:SYK - Get Rating) last posted its quarterly earnings data on Tuesday, July 26th. The medical technology company reported $2.25 EPS for the quarter, missing analysts' consensus estimates of $2.28 by ($0.03). Stryker had a return on equity of 23.34% and a net margin of 11.79%. During the same period in the prior year, the business posted $2.25 EPS. Analysts predict that Stryker will post 9.38 earnings per share for the current fiscal year. Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be issued a $0.695 dividend. The ex-dividend date is Thursday, September 29th. This represents a $2.78 dividend on an annualized basis and a dividend yield of 1.29%. Stryker's dividend payout ratio (DPR) is presently 51.20%. Institutional Investors Weigh In On Stryker

Several large investors have recently added to or reduced their stakes in SYK. Claremont Financial Group Inc. acquired a new stake in shares of Stryker in the first quarter worth $25,000. Cassady Schiller Wealth Management LLC purchased a new position in Stryker during the fourth quarter valued at $27,000. Retirement Group LLC lifted its holdings in Stryker by 86.8% during the fourth quarter. Retirement Group LLC now owns 99 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 46 shares in the last quarter. Exane Derivatives purchased a new position in Stryker during the first quarter valued at $27,000. Finally, Princeton Global Asset Management LLC lifted its holdings in Stryker by 1,212.5% during the first quarter. Princeton Global Asset Management LLC now owns 105 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 97 shares in the last quarter. 74.52% of the stock is owned by hedge funds and other institutional investors. About Stryker (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.Featured StoriesGet a free copy of the StockNews.com research report on Stryker (SYK)MarketBeat: Week in Review 8/1 - 8/5How to Use High Beta Stocks to Maximize Your Investing ProfitsCronos Group Inc's Revenues Are Up, Is It Time to Buy?Beyond Meat Is Not Beyond Hope, And It's CheapWhy Apple Could Be At All-Time Highs By Year End

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Today, Kate’s guest is Rhys Williams, chief investment officer for the Opportunistic All Cap Equity, a long-short strategy at Spouting Rock Asset Management.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.